Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

The Company also reported that all available patients from the ANA598 200 mg arm who were previously reported to have undetectable levels of virus at Week 24 and continued on pegylated interferon and ribavirin (current standard of care, or SOC) also maintained undetectable levels of virus at Week 36.  In addition, all patients from the ANA598 400 mg arm who were previously reported to have undetectable levels of virus at Week 12 and continued on SOC maintained undetectable levels of virus at Week 24.  ANA598, Anadys' direct-acting antiviral or DAA, is being developed to treat hepatitis C and is in an ongoing Phase II trial in combination with pegylated interferon and ribavirin.

"The SVR12 data reported today for ANA598 are highly encouraging," said Steve Worland, Ph.D., President and CEO of Anadys.  "These data illustrate the potential for HCV patients to be successfully treated with shortened courses of treatment, reflecting the continuing benefit of ANA598 post-therapy.  We believe these data, coupled with the excellent barrier to resistance demonstrated in this trial as well as the favorable safety and tolerability, confirm ANA598's position as one of the most attractive agents in Phase II HCV development today."

The si
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 The ... non-profit professional association serving more than 4,500 compliance ... its 2015 SCALENDAR, which chronicles corporate fines and ... and ethics professionals have a ready reference to ... "We developed the SCALENDAR to help compliance ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 Research ... "The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition" ... volume covers the entirety of the clinical testing market and ... Used by Top IVD Companies For Business Planning. ... volume based on the market events of 2013 and early ...
(Date:9/15/2014)... 15, 2014  Decision Resources Group finds that as ... increasing pressure to control expenditures will result in mounting ... although type 2 diabetes drugs will generally be reimbursable ... enforce additional restrictions on expensive agents. Surveyed physicians in ... Germany , Italy , ...
Breaking Medicine Technology:More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 2Interviewed Payers in the EU5 Anticipate Increasing Prescribing Constraints for Premium-Priced Type 2 Diabetes Agents 3
... 2012 /PRNewswire/ --   Masimo (NASDAQ: ... CO-Oximetry™, rainbow® Acoustic Monitoring™, and Masimo SET ® ... that Essential Medical Devices, Inc. dismissed all outstanding claims ... against Masimo and Cercacor.   Masimo did not incur any ...
... 2012   ulrich medical USA, Inc., today announced the ... new titanium vertebral body replacement device that is intended for ... a collapsed, damaged or unstable vertebral body due to tumor ... implant joins a distinguished and growing portfolio of expandable cage ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4ulrich medical USA™ Releases New Expandable Spinal Implant for US Market 2
(Date:9/16/2014)... QuickMedical, a national leader in the ... veteran-owned small business has officially launched three new ... Nipro Medical, and CP Medical Sutures. , ... best, most affordable medical equipment and supplies. To ... effort to reach new medical facilities, QuickMedical has ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 True Science Cosmetics, ... lip gloss that true-ly pampers lips from the inside out ... all day. , “The creation of true lipz™ came about ... dry, dehydrated lips no matter what products we used. ... looked great on, but could actually hydrate and moisturize throughout ...
(Date:9/16/2014)... New Jersey (PRWEB) September 16, 2014 ... healthbeautydistributors.com, the drug-free, FDA approved Cefaly device for chronic ... 2014 for sales in the United States. Until now, ... with the manufacturer located in Belgium and wait 2-3 ... is located in the United States and once prescription ...
(Date:9/16/2014)... peep-toe shoe is a woman's shoe (usually a pump, ... which there is an opening at the toe-box which ... beginning in the 1940s, but disappeared by the 1960s. ... before falling out of fashion by the mid-1990s. More ... such as "peep-toe boots" appearing. After months of preparation ...
(Date:9/15/2014)... Club wear is provocative, revealing, or fetish clothing that is ... relaxed dress code. There are various types of clothing items ... of the club, the club's dress code and the weather. ... delightedly pronounced its new series of delicate club wears; all ... A nightclub (also known as a discothèque, or simply a ...
Breaking Medicine News(10 mins):Health News:True Science Cosmetics, LLC Launches True Lipz™ 2Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:Nice Peep Toes Are For Sale At Fecbek.com 2Health News:Delicate Club Wears Are For Sale At Fecbek.com 2
... you that already! Older adults are more ... shared or not shared information with, according to a new ... the kind of memory faux pas that can lead to ... doctor,s office. Ironically, after making these memory errors older adults ...
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay ... pain in patients with nerve pain stemming from injuries ... with chronic nerve pain were taught to take a ... pipe, three times a day, for five days. The ...
... Quebec, Australia and the United Kingdom by publicly ... CMAJ ( Canadian Medical Association Journal ) (pre-embargo ... million Canadians (19% of the population) currently use ... recent years. A 2009 review of studies indicates ...
... 30 August 2010 - The notion that cutting or ... difficult to understand for most people, but it is ... themselves. Individuals with borderline personality disorder experience ... regulation skills. This group of people also displays high ...
... heart rhythm disorder is resulting in an alarming number ... A research team led by Professor Prash Sanders, ... Centre at the Royal Adelaide Hospital, found that hospital ... in Australia over a 15-year period. These findings ...
... Elsevier, a world-leading publisher of scientific, technical ... the launch of SciVerse, an innovative platform that ... scientific community to collaborate on the development of ... to releasing the APIs (application programming interfaces) for ...
Cached Medicine News:Health News:Older adults experience 'destination amnesia' 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Hurts so good -- neural clues to the calming effects of self-harm 2Health News:Heart disorder hits national epidemic proportions 2Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: